Skip to main content
. 2021 Dec 16;28(6):5401–5407. doi: 10.3390/curroncol28060450

Figure 3.

Figure 3

Axial CT image of lung (A) lesion before the start of combined lenvatinib/pembrolizumab treatment and (B) after 18 months of treatment; representative 18FDG-PET/CT images (C) at the initiation of the combined lenvatinib/pembrolizumab treatment and (D) after 18 months of treatment.